Amylin Analogues
2 compounds in this family, each with its recorded mechanism, routes of administration, safety notes and references to published literature.
- CagrilintideCagrilintide is an investigational amylin analogue administered by subcutaneous injection. It is being studied alone and in combination with the GLP‑1 receptor agonist semaglutide (CagriSema) for the treatment of obesity and type 2 diabetes, with the aim of producing greater weight loss and improved glycaemic control than existing therapies.
- PramlintidePramlintide is a synthetic analogue of the pancreatic hormone amylin, approved in the United States for use as an adjunct to insulin in adults with type 1 diabetes and insulin‑requiring type 2 diabetes. Delivered by subcutaneous injection, it lowers post‑prandial glucose and modestly reduces body weight, making it a candidate for obesity treatment under investigation.